The Lancet Rheumatology in conversation with

Fiona Pearce and Rachel Tattersall on HLH mortality rates in Europe

The Lancet Group

This months episode covers Hemophagocytic lymphohistiocytosis, or HLH, a rare, life-threatening disorder characterised by dysregulated immune activity resulting in systemic inflammation, tissue damage and multiorgan failure which affects both children and adults.
The annual prevalence of HLH in England is around 2 per million people in the adult population, with an overall 1-year survival rate of around 50% and similar rates have also been reported in other countries across the world. However, as most studies of HLH prevalence primarily focus on single nations and specific subpopulations, epidemiological data on global incidence and mortality rates are scarce.
Dr Fiona Pearce and Dr Rachel Tattersall discuss their recent publication in The Lancet Rheumatology which looked at mortality rates of HLH across Europe, we also discuss what manifestations clinicians should be looking out for and what’s next for HLH research.

Click here to read the full article: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00292-9/fulltext

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv